A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. JAGTAR SINGH			
AGE/ GENDER	: 53 YRS/MALE	1	PATIENT ID	: 1288734
COLLECTED BY	:	1	REG. NO./LAB NO.	: 122410010013
REFERRED BY	:	1	REGISTRATION DATE	: 01/Oct/2024 11:09 AM
BARCODE NO.	: 12505015		COLLECTION DATE	: 01/Oct/2024 11:36AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE IN	STITUTE I	REPORTING DATE	:01/Oct/2024 01:00PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, A	MBALA CITY - HAR	YANA	
Test Name		Value	Unit	Biological Reference interval
	CLIN		RY/BIOCHEMISTR	Y
		CAL	CIUM	
CALCIUM: SERUM by ARSENAZO III, SPE	CTROPHOTOMETRY	10.42	mg/dL	8.50 - 10.60
<u>INTERPRETATION:-</u> 1 Serum calcium (tot	al) estimation is used for the di	agnosis and monito	ring of a wide range of di	sorders including diseases of bone, kidney,
	r gastrointestinal tract.	agnosis and monito		solutions including diseases of bone, kidney,
	y also reflect abnormal vitamin			
				9% is present as calcium hydroxyapatite in bon-
	n the extra-osseous intracellular			the form of income is a multiple of the COV is
		nt to proteins (appr	oximately 40%), 10% is in	the form of inorganic complexes, and 50% is
present as free or ior		art and the skeletal	musculature and are esse	ential for the function of the nervous system. I

NOTE:-Calcium ions affect the contractility of the heart and the skeletal musculature, and are essential for the function of the nervous system. In addition, calcium ions play an important role in blood clotting and bone mineralization.

HYPOCALCEMIA (LOW CALCIUM LEVELS) CAUSES :-

1. Due to the absence or impaired function of the parathyroid glands or impaired vitamin-D synthesis.

2. Chronic renal failure is also frequently associated with hypocalcemia due to decreased vitamin-D synthesis as well as hyperphosphatemia and skeletal resistance to the action of parathyroid hormone (PTH).

3. NOTE:- A characteristic symptom of hypocalcemia is latent or manifest tetany and osteomalacia.

HYPERCALCEMIA (INCREASE CALCIUM LEVELS) CAUSES:-

1. Increased mobilization of calcium from the skeletal system or increased intestinal absorption.

2. Primary hyperparathyroidism (pHPT)

3.Bone metastasis of carcinoma of the breast, prostate, thyroid gland, or lung

NOTE:-Severe hypercalcemia may result in cardiac arrhythmia.





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

NOT VALID FOR MEDICO LEGAL PURPOSE





A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

AME	: Mr. JAGTAR SING	H				
GE/ GENDER	: 53 YRS/MALE	РАТ	TENT ID	: 1288734		
OLLECTED BY	:	REG	. NO./LAB NO.	: 122410010013		
EFERRED BY	:	REG	ISTRATION DATE	: 01/Oct/2024 11:09 AM		
ARCODE NO.	: 12505015	COL	LECTION DATE	: 01/Oct/2024 11:36AM		
LIENT CODE.	: P.K.R JAIN HEALT	HCARE INSTITUTE REP	ORTING DATE	: 01/Oct/2024 01:00PM		
LIENT ADDRESS	: NASIRPUR, HISSA	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA				
est Name		Value	Unit	Biological Reference interval		
		ELECTROLYTES CON	IPLETE PROFILE			
odium: serum		140	mmol/L	135.0 - 150.0		
by ISE (ION SELECTIVE	ELECTRODE)	4 5 1		2.50 5.00		
OTASSIUM: SERUM by ISE (ION SELECTIVE	ELECTRODE)	4.51	mmol/L	3.50 - 5.00		
	,	105	mmol/L	90.0 - 110.0		
alance & to transmit IYPONATREMIA (LOW . Low sodium intake. . Sodium loss due to . Diuretics abuses. 4. Salt loosing nephro . Metabolic acidosis.	ation of extra-cellul nerve impulse. SODIUM LEVEL) CA diarrhea & vomiting pathy.			y maintain osmotic pressure & acid base		
by ISE (ION SELECTIVE <u>NTERPRETATION:-</u> ODIUM:- odium is the major c. alance & to transmit IYPONATREMIA (LOW . Low sodium intake. . Sodium loss due to . Diuretics abuses. 4. Salt loosing nephro	ation of extra-cellul nerve impulse. SODIUM LEVEL) CA diarrhea & vomiting pathy. ficiency . REASED SODIUM LEV	USES:- with adequate water and iadequa		y maintain osmotic pressure & acid base		

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE





A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. JAGTAR SINGH		
AGE/ GENDER	: 53 YRS/MALE	PATIENT ID	: 1288734
COLLECTED BY	:	REG. NO./LAB NO.	: 122410010013
REFERRED BY	:	REGISTRATION DATE	: 01/Oct/2024 11:09 AM
BARCODE NO.	: 12505015	COLLECTION DATE	: 01/Oct/2024 11:36AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	REPORTING DATE	: 01/Oct/2024 01:00PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - H	IARYANA	

Test Name Value Unit **Biological Reference interval**

4. Hemolysis of blood





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	RI RI RI CC TUTE RI BALA CITY - HARY Value VITAN MIN D/25 HYD 21.63 ^L < 20 21 - 29 30 - 100 > 100 alciferol (from pla the skin upon Ult and transport form circulation.	Unit /IINS ROXY VITAMIN D3 ng/mL	: 01/Oct : 01/Oct : 01/Oct	34 10010013 t/2024 11:09 AM t/2024 11:36AM t/2024 01:00PM Biological Reference interval DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0 I (from animals, Vitamin D3), or by
VITA IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 in body resevoir a sport protein while in n the maintenance of	RI CC TUTE RI BALA CITY - HARY Value VITAN MIN D/25 HYD 21.63 ^L < 20 21 - 29 30 - 100 > 100 alciferol (from pla o the skin upon Ufr o the skin upon Ufr	EGISTRATION DATE DILECTION DATE EPORTING DATE ANA Unit MINS ROXY VITAMIN D3 ng/mL	: 01/Oct : 01/Oct : 01/Oct	t/2024 11:09 AM t/2024 11:36AM t/2024 01:00PM Biological Reference interval DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
VITA IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 in body resevoir a sport protein while in n the maintenance of	CO TUTE RI BALA CITY - HARY Value VITAN MIN D/25 HYD 21.63 ^L < 20 21 - 29 30 - 100 > 100 alciferol (from pla the skin upon Ultan othe skin upon Ultan the skin upon Ultan	DILECTION DATE EPORTING DATE ANA Unit /IINS ROXY VITAMIN D3 ng/mL	: 01/Oct : 01/Oct	t/2024 11:36AM t/2024 01:00PM Biological Reference interval DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
VITA IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 in body resevoir a sport protein while in n the maintenance of	TUTE RI BALA CITY - HARY Value VITAN MIN D/25 HYD 21.63 ^L < 20 21 - 29 30 - 100 > 100 alciferol (from pla o the skin upon Ult and transport form circulation.	EPORTING DATE ANA Unit /IINS ROXY VITAMIN D3 ng/mL	: 01/Oct	biological Reference interval DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
R, HISSAR ROAD, AME VITA VITA IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	TUTE RI BALA CITY - HARY Value VITAN MIN D/25 HYD 21.63 ^L < 20 21 - 29 30 - 100 > 100 alciferol (from pla o the skin upon Ult and transport form circulation.	EPORTING DATE ANA Unit /IINS ROXY VITAMIN D3 ng/mL	ng/mL ng/mL ng/mL ng/mL ng/mL	Biological Reference interval DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
R, HISSAR ROAD, AME VITA VITA IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	Value Value VITAN MIN D/25 HYD 21.63 ^L 21.63 ^L	Unit /IINS ROXY VITAMIN D3 ng/mL	ng/mL ng/mL ng/mL ng/mL ng/mL	Biological Reference interval DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
VITA IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	Value VITAN MIN D/25 HYD 21.63 ^L < 20 21 - 29 30 - 100 alciferol (from pla the skin upon Uli and transport form circulation.	Unit /IINS ROXY VITAMIN D3 ng/mL	ng/mL ng/mL ng/mL ng/mL	DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	VITAN MIN D/25 HYD 21.63 ^L 21.63 ^L 21 - 29 30 - 100 > 100 alciferol (from pla the skin upon Ul' on the skin upon Ul' the skin upon Ul' the skin upon Ul' the skin upon Ul'	AINS ROXY VITAMIN D3 ng/mL	ng/mL ng/mL ng/mL ng/mL	DEFICIENCY: < 20.0 INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	MIN D/25 HYD 21.63 ^L < 20	ROXY VITAMIN D3 ng/mL	ng/mL ng/mL ng/mL ng/mL	INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
IIN D3): SERUM MUNOASSAY) ed from dietary ergoca iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	21.63 ^L < 20 21 - 29 30 - 100 > 100 alciferol (from pla in the skin upon Uli and transport form i circulation.	ng/mL	ng/mL ng/mL ng/mL ng/mL	INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
ed from dietary ergoc: iferol to Vitamin D3 ir e main body resevoir sport protein while in n the maintenance of	 < 20 21 - 29 30 - 100 > 100 alciferol (from pla of the skin upon Uli and transport form i circulation. 	nts. Vitamin D2), or ch raviolet exposure.	ng/mL ng/mL ng/mL	INSUFFICIENCY: 20.0 - 30.0 SUFFICIENCY: 30.0 - 100.0 TOXICITY: > 100.0
iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	21 - 29 30 - 100 > 100 alciferol (from pla the skin upon Uli and transport form i circulation.	nts. Vitamin D2), or ch	ng/mL ng/mL ng/mL	I (from animals, Vitamin D3), or by
iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	30 - 100 > 100 alciferol (from pla the skin upon Uli and transport form circulation.	nts, Vitamin D2), or ch	ng/mL ng/mL	I (from animals, Vitamin D3), or by
iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	> 100 alciferol (from pla n the skin upon Ul and transport form circulation.	nts, Vitamin D2), or ch raviolet exposure.	ng/mL	I (from animals, Vitamin D3), or by
iferol to Vitamin D3 ir e main body resevoir a sport protein while in n the maintenance of	alciferol (from pla the skin upon Ul and transport form circulation.	nts, Vitamin D2), or ch raviolet exposure.		 I (from animals, Vitamin D3), or by
illure to mineralize ne on (celiac disease) hydroxylase activity ease perparathroidism (Mil leptic drugs like pheny is seen only after pro nophatemia. deficient individuals i	alcium mobilizatio wly formed osteo Id to Moderate de ytoin, phenobarbi longed exposure t must be monitore	n, mainly regulated by id in bone, resulting in ficiency) tal and carbamazepine o extremely high dose d by periodic assessme	e, that increa es of Vitamin ent of Vitami	nildren and osteomalacia in adults. ases Vitamin D metabolism. I D. When it occurs, it can result in in D levels in order to prevent
ea pe le le	ase erparathroidism (Mil eptic drugs like pheny s seen only after pro ophatemia. deficient individuals compare to whites, is	ase erparathroidism (Mild to Moderate de eptic drugs like phenytoin, phenobarbit s seen only after prolonged exposure t ophatemia. deficient individuals must be monitored compare to whites, is at higher risk of de	ase erparathroidism (Mild to Moderate deficiency) eptic drugs like phenytoin, phenobarbital and carbamazepine s seen only after prolonged exposure to extremely high dose ophatemia. deficient individuals must be monitored by periodic assessme compare to whites, is at higher risk of developing Vitamin D def	ase erparathroidism (Mild to Moderate deficiency) eptic drugs like phenytoin, phenobarbital and carbamazepine, that increas s seen only after prolonged exposure to extremely high doses of Vitamin ophatemia. deficient individuals must be monitored by periodic assessment of Vitami compare to whites, is at higher risk of developing Vitamin D deficiency due t



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

NOT VALID FOR MEDICO LEGAL PURPOSE



A PIONEER DIAGNOSTIC CENTRE

🕻 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. JAGTAR SINGH			
AGE/ GENDER	: 53 YRS/MALE	РАТ	TENT ID	: 1288734
COLLECTED BY	:	REG	. NO./LAB NO.	: 122410010013
REFERRED BY	:	REG	ISTRATION DATE	: 01/Oct/2024 11:09 AM
BARCODE NO.	: 12505015	COL	LECTION DATE	:01/Oct/2024 11:36AM
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INST	ITUTE Rep	ORTING DATE	:01/Oct/2024 01:00PM
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMI	BALA CITY - HARYAI	NA	
Test Name		Value	Unit	Biological Reference interva
			•	2.0.09.00.0.0.0.000
		VITAMIN B12/C	OBALAMIN	
VITAMIN B12/COBA		240.4	C OBALAMIN pg/mL	200.0 - 1100.0
VITAMIN B12/COBA by CMIA (CHEMILUMIN	LAMIN: SERUM IESCENT MICROPARTICLE IMMUNOASS	240.4		200.0 - 1100.0
VITAMIN B12/COBA by CMIA (CHEMILUMIN INTERPRETATION:-	ESCENT MICROPARTICLE IMMUNOASS	240.4	pg/mL	
VITAMIN B12/COBA by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS	ESCENT MICROPARTICLE IMMUNOASS	240.4		
VITAMIN B12/COBA by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan	IESCENT MICROPARTICLE IMMUNOASS SED VITAMIN B12 nin C	240.4 SAY)	pg/mL DECREASED VITAMIN I	B12
VITAMIN B12/COBA by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro	IESCENT MICROPARTICLE IMMUNOASS SED VITAMIN B12 hin C gen	240.4 SAY) 1.Pregnancy 2.DRUGS:Asp	pg/mL DECREASED VITAMIN I	B12
VITAMIN B12/COBA by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro 3.Ingestion of Vitan	IESCENT MICROPARTICLE IMMUNOASS SED VITAMIN B12 hin C gen hin A	240.4 SAY) 1.Pregnancy 2.DRUGS:Asp 3.Ethanol Ige	pg/mL DECREASED VITAMIN I Dirin, Anti-convulsants, C	B12
VITAMIN B12/COBA by CMIA (CHEMILUMIN INTERPRETATION:- INCREAS 1.Ingestion of Vitan 2.Ingestion of Estro	IESCENT MICROPARTICLE IMMUNOASS ED VITAMIN B12 nin C gen nin A jury	240.4 SAY) 1.Pregnancy 2.DRUGS:Asp 3.Ethanol Ige	pg/mL DECREASED VITAMIN I pirin, Anti-convulsants, (estion tive Harmones	B12

excreted. 4.Vitamin B12 deficiency may be due to lack of IF secretion by gastric mucosa (eg, gastrectomy, gastric atrophy) or intestinal malabsorption (eg,

5. Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of

proprioception, poor coordination, and affective behavioral changes. These manifestations may occur in any combination; many patients have the neurologic defects without macrocytic anemia.

6.Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states.

7.Follow-up testing for antibodies to intrinsic factor (IF) is recommended to identify this potential cause of vitamin B12 malabsorption. **NOTE:**A normal serum concentration of vitamin B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for vitamin B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum vitamin B12 concentrations are normal.

*** End Of Report ***



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

